Alpelisib + Fulvestrant
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Advanced Breast Cancer
Conditions
Advanced Breast Cancer
Trial Timeline
Aug 9, 2022 → Jun 12, 2025
NCT ID
NCT05631795About Alpelisib + Fulvestrant
Alpelisib + Fulvestrant is a approved stage product being developed by Novartis for Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05631795. Target conditions include Advanced Breast Cancer.
What happened to similar drugs?
15 of 20 similar drugs in Advanced Breast Cancer were approved
Approved (15) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05631795 | Approved | Completed |
| NCT04524000 | Phase 2 | Active |
Competing Products
20 competing products in Advanced Breast Cancer